Healius Limited is a leading Australian healthcare company specializing in diagnostic services, with a particular emphasis on pathology and medical imaging. As a key provider across the health care services industry, Healius operates an extensive network of pathology laboratories, patient collection centers, and diagnostic imaging sites covering metropolitan, regional, and remote regions throughout Australia. The company’s brands include Laverty Pathology, QML Pathology, Dorevitch Pathology, Genomic Diagnostics, Abbott Pathology, IQ Pathology, and Lumus Imaging, among others, reflecting its broad reach in both human and veterinary diagnostics. Healius serves a critical function in the health sector by supplying high-quality, cost-efficient, and accessible diagnostic solutions to healthcare practitioners, hospitals, and consumers. Its robust infrastructure and technological capabilities enable it to support clinical trials, specialty pathology, and advanced imaging, underlining its role as an essential backbone for healthcare delivery and medical decision-making nationwide. The company’s market significance rests in its capacity to drive healthcare outcomes through the integration of technology and clinical expertise, supporting Australia’s public and private healthcare systems.